FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

2 sources ·2 articles ·7h ago

2 outlets - including Biopharmadive and Marketwatch - are covering this story. Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

Covered by 2 outlets

Biopharmadive 1 Marketwatch 1

All coverage · 2 articles

BioPharma Dive ·7h ago

Grail multicancer detection test wins FDA advisers’ backing

Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

MarketWatch Top Stories ·Sep 23, 12:39 UTC

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Grail multicancer detection test wins FDA advisers’ backing →

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. →

Grail multicancer detection test wins FDA advisers’ backing

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.